Characterization of the C6D7-RBD Human Monoclonal Antibody Specific to the SARS-CoV-2 S Protein Receptor-Binding Domain

Acta Naturae

article

Yana O. Romanenko¹  Marina V. Silkina¹  Alena S. Kartseva¹  Maksim A. Marin¹  Maria A. Shkuratova¹  Maria A. Makarova¹  Alena K. Ryabko¹  Daria A. Konyshkova¹  Natalia A. Zeninskaya¹  Anna E. Khlyntseva¹  Igor G. Shemyakin¹  Victoria V. Firstova¹ 

[1] Federal Budget Institution of Science State Research Center for Applied Microbiology and Biotechnology

关键词: COVID-19;    SARS-CoV-2;    receptor-binding domain;    human monoclonal antibody;    virus-neutralizing activity;   

DOI  :  10.32607/actanaturae.11849

学科分类：生物技术

来源: Moskovskii Gosudarstvennyi Universitet im.M.V.Lomonosova/M.V.Lomonosov Moscow State University

【 摘 要 】

The new coronavirus infection COVID-19 is an acute viral disease that affects primarily the upper respiratory tract. The etiological agent of COVID-19 is the SARS-CoV-2 RNA virus (Coronaviridae family, Betacoronavirus genus, Sarbecovirus subgenus). We have developed a high-affinity human monoclonal antibody, called C6D7-RBD, which is specific to the S protein receptor-binding domain (RBD) from the SARS-CoV-2 Wuhan-Hu-1 strain and exhibits virus-neutralizing activity in a test with recombinant antigens: angiotensin-converting enzyme 2 (ACE2) and RBD.

【 授权许可】

Unknown